<DOC>
	<DOCNO>NCT00554229</DOCNO>
	<brief_summary>Enthuse M1 large phase III clinical trial study safety efficacy ZD4054 ( Zibotentan ) patient hormone resistant prostate cancer bone metastasis . - This clinical trial test Endothelin A Receptor Antagonist ZD4054 ( Zibotentan ) improve survival compare placebo . - ZD4054 ( Zibotentan ) new type agent , think slow tumour growth spread block Endothelin A receptor activity . This trial look effect ZD4054 ( Zibotentan ) hormone resistant prostate cancer patient bone metastasis . - All patient participate clinical trial receive exist standard prostate cancer treatment addition trial therapy . - Half patient receive ZD4054 ( Zibotentan ) , half patient receive placebo addition standard prostate cancer therapy . By participate trial 50 % chance patient receive agent may slow progression tumour . - No patient deprive standard prostate cancer therapy .</brief_summary>
	<brief_title>A Phase III Trial ZD4054 ( Zibotentan ) ( Endothelin A Antagonist ) Hormone Resistant Prostate Cancer With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Endothelin A Receptor Antagonists</mesh_term>
	<criteria>Patients answer TRUE follow criterion may eligible participate trial . 1 . Confirmed diagnosis prostate cancer ( adenocarcinoma prostate ) spread bone ( bone metastasis ) 2 . Increasing Prostate Specific Antigen ( PSA ) one month period 3 . No pain , mild pain prostate cancer 4 . Currently receive treatment surgical medical castration Patients answer TRUE follow may NOT eligible participate trial . 1 . Currently use opiate base pain killer ) 2 . Previous treatment chemotherapy ( paclitaxel , docetaxel , mitoxantrone ) 3 . Suffering heart failure myocardial infarction within last 6 month 4 . A history epilepsy seizure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hormone Resistant Prostate Cancer</keyword>
	<keyword>Endothelin A Receptor Antagonist</keyword>
	<keyword>Endothelin A</keyword>
	<keyword>Endothelin A antagonist</keyword>
</DOC>